SciSparc Reports Quantum-Enabled Gene Analysis Acceleration
(RTTNews) - SciSparc Ltd. (SPRC), through its majority-owned subsidiary NeuroThera Labs (NTLX.V), announced that subsidiary CliniQuantum reported successful quantum-enabled analysis of billions of gene combinations using real-world clinical data.
CliniQuantum's GPU-accelerated quantum-simulation platform achieved approximately 16.8-fold computational acceleration compared with a CPU-only implementation on the same 64-vCPU machine.
The evaluation used clinical gene-expression data from 11 patients containing 3,531 gene-expression features, representing a high-dimensional dataset with substantially more biological variables than patients.
CliniQuantum's algorithm searched for correlated three-gene configurations, generating approximately 7.33 billion possible three-gene combinations from the 3,531 genes.
Using a predefined minimum correlation threshold, the analysis identified approximately 22.2 million correlated gene triplets.
The analysis required about 8.4 hours using 64 vCPUs, compared with approximately 0.5 hours using a single NVIDIA T4 Tensor Core GPU, while producing the same qualifying gene-triplet results.
The benchmark was conducted on an AWS EC2 machine using IBM Qiskit Aer GPU-based quantum simulation and was designed to evaluate computational performance, not the clinical validity or predictive value of the identified gene combinations.
CliniQuantum plans to advance its algorithms toward increasingly complex multi-feature configurations and larger biomedical datasets, while progressing from simulation and validation toward execution on quantum computing hardware.
SciSparc, through NeuroThera, is engaged in clinical-stage pharmaceutical development focused on cannabinoid-based therapies for central nervous system disorders and other underserved conditions.
SPRC shares Tuesday's closed at $4.33, down 0.69%. In the premarket, stock is up 5.65% at $4.49.
NTLX.V closed Thursday's trading (October,01, 2026) at CAD 4.40 without any movement on the TSX Venture Exchange.
